Traditional sterility testing is inherently slow, creating operational bottlenecks throughout the entire manufacturing workflow. In this Q&A, Dewitt Jones, Global Sales Director with Thermo Fisher Scientific, and Mike Auerbach, Editor-In-Chief at American Pharmaceutical Review, discuss specific ways rapid sterility testing technologies, such as qPCR-based detection, address the limitations of traditional sterility testing.
Watch now to learn more about validation requirements of rapid sterility testing, incorporating rapid sterility testing into cell therapy manufacturing workflows, and how rapid sterility testing can improve risk mitigation and reduce the likelihood of releasing contaminated cell therapy products.